Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories' Lexapro leads first-line therapy in the treatment of major depression. According to the new report entitled Treatment Algorithms in Major Depression, selective serotonin reuptake inhibitors (SSRIs), which include Lexapro, serve 63.6 percent of patients on first-line therapy. Surveyed physicians say the reasons for SSRIs being so heavily used are efficacy, cost and physician familiarity. Eighty percent of surveyed psychiatrists and 70 percent of surveyed primary care physicians (PCPs) say they choose SSRIs over benzodiazepines because of efficacy. Forty-nine percent of surveyed psychiatrists cite cost as the prime reason they choose SSRIs over serotonin/norepinephrine reuptake inhibitors (SNRIs), while 49 percent of PCPs say they choose SSRIs over SNRIs owing to familiarity with the former class.
The report also finds that psychiatrists and PCPs do not all agree on what the most effective drugs are for treatment of major depression; therefore, there is significant variation in the choice of agent, with no clear dominant player. Forty-four percent of surveyed PCPs say SSRIs are more effective than SNRIs, but 72 percent of psychiatrists believe the opposite. Sixty-two percent of surveyed PCPs think Lexapro's efficacy against depression is a major reason to choose it, but only 24 percent of surveyed psychiatrists agree.
"We project a significant increase in the use of atypical antipsychotics as adjunct therapies in the next two years," said Michael Malecki, Ph.D., analyst at Decision Resources. "Thirty-six percent of surveyed psychiatrists and 27 percent of surveyed PCPs say they will more frequently prescribe antipsychotics as adjunct therapies. The majority of prescriptions for antipsychotics in major depression are initiated by psychiatrists; thus, we believe psychiatrists' prescribing patterns will drive the use of these agents in the near term."
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics® to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.
For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides the following:
-- Summary of U.S. medical practice based on interviews with leading experts in the field. -- Qualitative diagnosis/referral/treatment algorithm for the United States. -- Drug usage by lines of therapy (1st, 2nd, 3rd line). -- Discussion of key freeform combinations by lines of therapy. -- Product share (class and specific compound level) within each line of therapy (1st, 2nd, 3rd line). -- Progression of therapy from key 1st line products. -- Pathway to key therapies from previous therapies. -- Qualitative analysis of two-year forecast incorporating upcoming launches, changes in reimbursement, etc. About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc. +1-781-296-2563,
Web site: http://www.decisionresources.com/